sb 203580 has been researched along with Brain Infarction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, S; Li, J; Liang, J; Liu, X; Luo, Y; Wang, Y; Yin, Y; Zhao, L | 1 |
| Han, PL; Kim, JB; Lee, JK; Piao, CS | 1 |
2 other study(ies) available for sb 203580 and Brain Infarction
| Article | Year |
|---|---|
Phosphorylation of p38 MAPK mediates hypoxic preconditioning-induced neuroprotection against cerebral ischemic injury via mitochondria translocation of Bcl-xL in mice.
Topics: Animals; bcl-X Protein; Brain Edema; Brain Infarction; Disease Models, Animal; Enzyme Inhibitors; Imidazoles; Immunoprecipitation; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Ischemic Preconditioning; Male; Mice; Mice, Inbred BALB C; Mitochondria; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Transport; Pyridines; Time Factors | 2013 |
Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Blotting, Western; Brain; Brain Infarction; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Gene Expression Regulation; Imidazoles; Immunohistochemistry; Infarction, Middle Cerebral Artery; Isoenzymes; Lectins; Male; Microglia; Mitogen-Activated Protein Kinase 14; Mitogen-Activated Protein Kinases; Neurologic Examination; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Time Factors | 2003 |